JOLTS Job Openings (Jun) 7.44M vs 7.5M Expected
IRVINE - Edwards Lifesciences (NYSE:EW) shares surged 7.6% after the medical device maker reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across all product groups.
The company reported adjusted earnings per share of $0.67, beating the analyst consensus of $0.62, while revenue climbed 11.9% to $1.53 billion, surpassing the $1.49 billion estimate. On an adjusted basis, revenue grew 10.6% compared to the same period last year.
Edwards’ Transcatheter Aortic Valve Replacement (TAVR) business, its largest segment, saw sales increase 8.9% to $1.13 billion, or 7.8% on a constant currency basis. The Transcatheter Mitral and Tricuspid Therapies (TMTT) division posted impressive growth of 61.9% to $134.5 million, while Surgical Structural Heart sales rose 7.7% to $266.8 million.
"We are pleased to report strong second quarter results that delivered double-digit sales growth," said Bernard Zovighian, CEO of Edwards Lifesciences. "Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance."
Following the strong performance, Edwards raised its full-year 2025 sales growth guidance to 9-10% from the previous 8-10% range. The company also increased its TAVR sales growth forecast to 6-7% from 5-7% and now expects adjusted EPS to be at the high end of its $2.40 to $2.50 range.
The company highlighted several recent achievements, including the SAPIEN platform becoming the only TAVR approved for asymptomatic patients in both the U.S. and Europe, and the CE Mark approval of SAPIEN M3, which strengthens Edwards’ comprehensive TMTT portfolio.
For the third quarter, Edwards projects total sales between $1.46 billion and $1.54 billion, with adjusted EPS of $0.54 to $0.60.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.